Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
BUSPIRONE, A 5-HYDROXYTRYPTAMINE(1A) AGONIST, IS ACTIVE IN CEREBELLAR-ATAXIA - RESULTS OF A DOUBLE-BLIND DRUG PLACEBO STUDY IN PATIENTS WITH CEREBELLAR CORTICAL ATROPHY
Autore:
TROUILLAS P; XIE J; ADELEINE P; MICHEL D; VIGHETTO A; HONNORAT J; DUMAS R; NIGHOGHOSSIAN N; LAURENT B;
Indirizzi:
HOP NEUROL,CTR RECH ATAXIE,59 BLVD PINEL F-69003 LYON FRANCE HOP NEUROL,CEREBROVASC UNIT F-69003 LYON FRANCE HOP NEUROL,NEUROOPHTHALMOL SERV F-69003 LYON FRANCE HOP NEUROL,BIOSTAT UNIT F-69003 LYON FRANCE UNIV LYON 1,ALEXIS CARREL SCH MED F-69365 LYON FRANCE BELLEVUE HOSP,NEUROL SERV ST ETIENNE FRANCE DIJON HOSP,NEUROL SERV DIJON FRANCE
Titolo Testata:
Archives of neurology
fascicolo: 6, volume: 54, anno: 1997,
pagine: 749 - 752
SICI:
0003-9942(1997)54:6<749:BA5AIA>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
THIAMINE-DEFICIENCY; LEVOROTATORY FORM; RECEPTORS; SEROTONIN; ANXIETY; IMPROVEMENT; ANXIOLYTICS; RESPONSES; DIAZEPAM; NEURONS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
42
Recensione:
Indirizzi per estratti:
Citazione:
P. Trouillas et al., "BUSPIRONE, A 5-HYDROXYTRYPTAMINE(1A) AGONIST, IS ACTIVE IN CEREBELLAR-ATAXIA - RESULTS OF A DOUBLE-BLIND DRUG PLACEBO STUDY IN PATIENTS WITH CEREBELLAR CORTICAL ATROPHY", Archives of neurology, 54(6), 1997, pp. 749-752

Abstract

Objective: To establish the antiataxic effect of buspirone hydrochloride, a serotonergic 5-hydroxytryptamine(1A) (5-HT1A) agonist, in a homogenous group of patients characterized by the same well-defined single condition, cerebellar cortical atrophy. Setting: University ataxia research center. Methods: Double-blind randomized study of buspirone vsplacebo during a dr-month period. Patients: Nineteen patients met theinclusion criteria; all completed the study. Of these 19 patients, 9 were treated with placebo and 10 were treated with the drug. Main Outcome Measurer: A semiquantitative scale for kinetic and static (''postural'') cerebellar functions; quantitative clinical measurements measuring time in standard tests that evaluated stance, speech, writing, anddrawing; and posturographic analysis of the sway path and sway area of the center-of-foot pressure. The primary end point was improvement of the posttherapeutic change of one of the semiquantitative ataxic scores. The secondary end points were modification of the changes of quantitative measures-clinical or posturographic. Results: In intention-to-treat analysis, a significant improvement of the primary end point, ie, the posttherapeutic change of the ataxic kinetic score, was shown. Among secondary end points, the maximum time of standing with feet together also was significantly improved. Conclusions: Buspirone is active in cerebellar ataxia of patients with cerebellar atrophy. These results confirm the data suggested by open-label studies with buspirone. However, the effect is partial and not clinically major. These pharmacological results might be due to serotonergic mechanisms and confirm a possible link between cerebellar ataxia and the metabolism of serotonin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 19:23:15